2026-01-02 - Analysis Report
Okay, here's a comprehensive analysis of Teladoc Health Inc. (TDOC) based on the information provided.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Teladoc Health Inc. is a telehealth company offering virtual healthcare services.
*   **Cumulative Return:** TDOC (-65.24%) significantly underperforms VOO (S&P 500) (105.07%).
*   **Divergence:** The divergence between TDOC and VOO is currently at -170.3, with a relative divergence of 0.4. This means the current divergence is near the *lowest end* of its historical range.
*   **Analysis of Alpha/Beta Table:**

    *   **Early High Growth (2016-2020):** TDOC demonstrated exceptional growth, with impressive CAGRs and Alphas. The Betas were relatively high, indicating greater volatility compared to the market.
    *   **Recent Struggles (2020-2025):** Performance has plummeted in recent years, with negative CAGRs and significantly negative Alphas. Betas remained high, indicating continued high volatility. The market cap has also shrunk significantly, going from over 35 billion to just over 1 billion.
    *   **Key Takeaway:** TDOC's performance has dramatically deteriorated in recent years, indicating significant underperformance compared to the broader market. While its early years showcased strong growth, recent times show a sharp reversal.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** \$7.0
*   **Recent Moving Averages:**
    *   5-day SMA: \$7.06
    *   20-day SMA: \$7.358
    *   60-day SMA: \$7.7868
*   **Analysis:** The stock price is below all three moving averages, suggesting a short-term downtrend. The 5-day SMA is closest to the current price, while the 60-day SMA is the furthest, indicating a longer-term downward trend. The 'change' is 0.0, which shows the prices are stagnating.

**3) RSI, PPO Index, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended). *Note that despite the MRI, the analysis in the first section showed that this stock is not doing well.*
*   **RSI:** 23.26 (Oversold).
*   **PPO:** -0.41 (Below Zero - bearish, but close to zero).
*   **Hybrid Signal:** "cash\_0% Buy 100% of cash (133 shares - Very Safe - MRI:0.90)" - The system recommends investing all available cash, but it's based on the high MRI, which is at odds with other bearish indicators and significant underperformance of the stock.
*   **Recent Divergence Change:** 0.4 (+): Short-term increase.
*   **Expected Return:** 0.0%. No expected excess return compared to the S&P 500 in the long term.

**4) Recent News & Significant Events**

*   **Key Headlines:**
    *   **Negative Sentiment:** Several articles suggest considering alternatives to TDOC. "Forget Teladoc and Buy This Healthcare Stock Instead". "Teladoc Health: Fading Hope".
    *   **Comparison:** Comparisons to competitors, such as HIMS, likely highlight TDOC's challenges.
    *   **Volatility:** "3 Volatile Stocks That Concern Us" indicates TDOC is considered a risky investment.
    *   **Temporary Bounce:** "Why Teladoc (TDOC) Stock Is Up Today" suggests short-term fluctuations rather than sustained positive momentum.
*   **Analysis:** Recent news is predominantly negative, focusing on TDOC's struggles, volatility, and less appealing prospects compared to competitors.

**4-2) Analyst Opinions**

*   **Consensus:** Analysts seem to be undecided on a specific rating (no key provided).
*   **Target Price:** Average target price of \$9.18, which is above the current price of \$7.0. However, the low target price is \$7.0, suggesting some analysts see little upside.
*   **Recent Rating Changes:** No information provided on recent rating changes, so no analysis possible.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| ----------- | ----- | -------- |
| 2025-10-30 | -0.28 | 0.63 B$ |
| 2025-07-30 | -0.19 | 0.63 B$ |
| 2025-05-01 | -0.53 | 0.63 B$ |
| 2024-10-31 | -0.19 | 0.64 B$ |
| 2025-10-30 | -0.19 | 0.64 B$ |

*   **Analysis:** EPS is consistently negative, indicating a lack of profitability. Revenue is relatively stable around \$0.63-0.64 billion. The consistency of negative EPS alongside steady revenue suggests issues with cost management or pricing.

**6) Financial Information**

*   **Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ----------- | -------- | --------------- |
| 2025-09-30 | \$0.63B | 70.12%          |
| 2025-06-30 | \$0.63B | 69.85%          |
| 2025-03-31 | \$0.63B | 68.73%          |
| 2024-12-31 | \$0.64B | 70.50%          |
| 2024-09-30 | \$0.64B | 71.94%          |

*   **Capital and Profitability:**

| Quarter      | Equity    | ROE       |
| ----------- | --------- | -------- |
| 2025-09-30 | \$1.39B | -3.56%   |
| 2025-06-30 | \$1.42B | -2.30%   |
| 2025-03-31 | \$1.43B | -6.52%   |
| 2024-12-31 | \$1.49B | -3.25%   |
| 2024-09-30 | \$1.51B | -2.21%   |

*   **Analysis:** Revenue is stable. Profit margins appear high, but ROE is negative, meaning that while the company is generating revenue and has good profit margins, it's not efficiently using equity to generate profit. Furthermore, the equity is gradually shrinking.

**7) Comprehensive Analysis (Summary)**

*   **Performance:** TDOC has significantly underperformed the S&P 500, particularly in recent years.
*   **Financials:** While revenue is stable and profit margins are high, consistent negative EPS and ROE indicate underlying profitability challenges. The equity is shrinking.
*   **Market Sentiment:** News articles and analyst opinions are largely negative, highlighting volatility and less appealing prospects compared to competitors.
*   **Technical Indicators:** RSI indicates an oversold condition, which *could* signal a potential bounce. However, the stock price is below its moving averages, suggesting a continued downtrend.
*   **Risk:** Despite a high MRI, multiple indicators and news suggest TDOC is a risky investment.
*   **Recommendation:** Based on the comprehensive analysis, **caution is advised.** While the oversold condition and analyst target price offer some hope, the negative earnings, underperformance, and negative news flow suggest significant challenges remain. The hybrid signal should be viewed skeptically given the other indicators.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.